The companies will combine the Binx io diagnostic platform with Sherlock Bio's CRISPR technology to create an easy-to-use rapid test for the point of care.
At the second virtual session of the AACR annual meeting, researchers also discussed how they're using CRISPR to develop better cancer models and reprogram T cells.
Christiana Care researchers have identified a unique protospacer adjacent motif site that allows them to knock out the NRF2 gene in tumor cells while leaving normal cells alone.
The firms are targeting a compatible offering for single-cell gene expression screens following CRISPR-based editing, with applications in drug discovery.
Sherlock Bio recently received US Food and Drug Administration Emergency Use Authorization for the kit, which uses CRISPR to detect the virus in patient samples.
The company said it is using the technology for synthetic biology, diagnosis of inherited genetic diseases, liquid biopsy, and infectious disease detection.
These hybrid capture-based methods target gene transcripts of interest, which could shrink sequencing costs for some experiments by as much as 90 percent.
Three teams have developed base editors that combine the abilities of adenine and cytosine base editors, allowing for concurrent A-to-G and C-to-T edits.
Silicon Valley venture capital firm Andreessen Horowitz led the round, joined by 8VC, SV Angel, Allen & Co, and several other undisclosed private investors.
The platform can detect a single virus in more than 1,000 samples at a time or more than 160 viruses, including SARS-CoV-2, in a small number of samples.
Agilent, which co-led Mission Bio's 2018 $30 million Series B financing round, will comarket the Tapestri platform to cancer researchers in North America.
The company's CRISPR-chrom technology fuses chromatin-modulating peptides to CRISPR nucleases, essentially moving chromatin out of the way for more efficient editing.
The researchers said their assay can be run in 30 to 45 minutes, with 95 percent positive predictive agreement and 100 percent negative predictive agreement.
Axxam said it will use the CRISPR technology to support the development of customized cell-based assays for targets and molecular pathways of interest.
The Cas9 variant can target nearly all PAM sites in the genome, allowing the researchers to edit previously inaccessible disease-relevant genetic variants.
In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.
